OSI eyes third party options after board rejects Astellas bid
16 March 2010
Ian Haydock
OSI Pharmaceuticals' board has unanimously rejected
Astellas's unsolicited $52 per share cash offer for the company, recommending that OSI shareholders do the same.
After a formal review, which included external advisors, the board's conclusion was that "the offer does not fully reflect OSI's...
Please Login to read the full article.
16 March 2010
Ian Haydock
After a formal review, which included external advisors, the board's conclusion was that "the offer does not fully reflect OSI's...
Please Login to read the full article.
RELATED CONTENT
FEATURES
- Chinese producers may be losing price edge to India, says Granules MD
- Merck BioVentures: where biosimilars make a difference
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
